GENERIC MEDICINES REGULATION IN BRAZIL
Journal Title: International Journal of Drug Regulatory Affairs - Year 2017, Vol 5, Issue 3
Abstract
The regulation of medicines in Brazil has proven to be one of the major concerns of government policies in recent decades. In order to improve access to quality medicines for the population, the National Drug Policy was instituted, culminating in the creation of the National Health Surveillance Agency (ANVISA) and the implementation of generic medicines policy. The generic medicines was effectively introduced in Brazil with the publication of the Law nº 9.787 in 1999, resulting from an objective of the Ministry of Health to significantly reduce the costs of pharmacological therapy, stimulate commercial competition and facilitate the population's access to drug treatment. In the same year the resolution no 391/1999 regarding the technical requirements for the registration of generics in Brazil was published. Since 1999, several legislation has been published in order to regulate the generic policy in Brazil. The present article summarises the legal framework for the implementation of the generic medicines in Brazil. It also describes the current technical requirements and legislation for the registration and maintenance of the register of generics in Brazil, according to ANVISA.
Authors and Affiliations
Priscila Aburachid Cardoso
Keywords
Related Articles
- EP ID EP326741
- DOI 10.22270/ijdra.v5i3.201
- Views 137
- Downloads 0
INTERNATIONAL CONFERENCE ON HARMONISATION: AN OVERVIEW
The International Conference on Harmonisation (ICH) is a project that makes together the regulatory bodies of Europe, Japan and the United States and professionals from the pharmaceutical domain in the three areas to dis...
TECHNOLOGY DVELOPMENT FOR POLYMER MODIFICATION TO ENHANCE SOLUBILITY OF POORLY SOLUBLE DRUG
Solubilization of poorly soluble drugs is a frequently encountered challenge in screening studies of new chemical entities as well as in formulation design and development. Solubility of some drugs is very less; these dr...
SCALE UP AND POSTAPPROVAL CHANGES (SUPAC) GUIDANCE FOR INDUSTRY: A REGULATORY NOTE
In today scenario, as per market demand there is definitely carry out an increment or decrease in production, this is called SUPAC. Different guidelines are provided for those different types of SUPAC in by different reg...
Nanoparticles and target Drug delivery for cancer treatment: A Comprehensive review
In the healthcare industry, the biggest challenges are cancer. However, there are several drugs are available for the treatment of cancer. In these treatments cure cancer affecting the collateral toxicity to healthy cell...
MARKETING AUTHORIZATION APPLICATION (MAA) FOR EUROPE MARKET
This article states requirement of Marketing Authorization Application to get registration of Drug Product to EEA. The procedures for application of marketing authorization are: Centralised procedure, National procedure,...